Baseball Daily News

Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update
GlobeNewswire (press release)
Initiated Phase 3 Trial for OTIVIDEX™ in Ménière's Disease: In July 2018, Otonomy announced initiation of the additional Phase 3 trial required to support submission for U.S. registration of OTIVIDEX in Ménière's disease. The design and conduct of
$250000.00 in Sales Expected for Otonomy Inc (OTIC) This QuarterBaseball Daily News

all 4 news articles »